Photo taken from Dana-Farber’s Breast Oncology Center/X
Apr 8, 2024, 14:26
Dana-Farber’s Breast Oncology Center is leading a trial for stage 1 HER2+ Breast Cancer of T-DM1 followed by SQ trastuzumab versus TH
Dana-Farber’s Breast Oncology Center posted on X:
“We are leading a randomized Phase 2 trial for stage 1 HER2+ Breast Cancer of T-DM1 followed by SQ trastuzumab versus TH (paclitaxel + SQ trastuzumab) (ATEMPT 2.0).”
Read further.
Source: Dana-Farber’s Breast Oncology Center/X
Jun 30, 2024, 00:34